Check out your Company Bowl for anonymous work chats.
Looking forward to presenting new data for olutasidenib in acute myeloid leukemia and FT-4202 in sickle cell disease at the 61st ASH meeting in December. Data from our internally-discovered and partnered program, FT-1101, to treat hematologic malignancies will also be featured. http://glassdoor.com/slink.htm?key=vMHxv
Our knitting group, FORMA Knits, proves we are a "tight-knit" group!
Last night FORMA took part in the Boston Light the Night walk. We raised over $21,000 for The Leukemia & Lymphoma Society, coming in third of all corporate fundraising teams! #formafuture #formafuturewithforma #lightthenight
Continuous learning is important at FORMA! This week, some Watertown employees visited our Branford site to learn about processes and capabilities in an effort to better understand the early discovery research process from start to finish across departments. #teamwork #formafuture #formafuturewithforma #formaconnection #formaknowledgebase #Branford #Watertown #formatherapeutics
FORMA sponsored the Leukemia & Lymphoma Society's Light the Night walk this past Saturday night and our team raised the most money for the cause! We care about the patients, our employees, and the community! #formafuture #lls #lightthenight #formafuturewithforma
Our tattoos are temporary but our commitment to the cause is not! FORMA was the top fundraiser for The Leukemia and Lymphoma Society’s Light the Night event this past Saturday night in Medford, MA! #formafuture #lightthenight #lls #formatherapeutics #formafuturewithforma
The fundraising competition is fierce here at FORMA leading up to the FORMA sponsored Light the Night walk in Medford, MA this Saturday night! Despite (or maybe because of?) the battle to see who can raise the most money, the FORMA team together has raised over $15,000 so far! We might fight with each other sometimes, but we fight cancer much harder. http://glassdoor.com/slink.htm?key=vM0rp
We've expanded our leadership team to include Jeannette Potts, Ph.D., J.D. as SVP, General Counsel & Corporate Secretary, Todd Shegog as SVP, CFO, Scott Boyle, Ph.D. as VP, Business and Corporate Development, and Brian Lesser as VP, Therapeutic Head. We’re glad to have their experience and leadership as we continue to develop our clinical assets and work towards delivering transformative medicines to patients. In addition, Pat Kelly has been promoted to SVP, CMO and Mary Wadlinger has been promoted to SVP, Corporate Affairs and Chief Human Resources Officer. See the full management team at http://glassdoor.com/slink.htm?key=vM0MB. http://glassdoor.com/slink.htm?key=vM0MF
Our most advanced clinical asset, olutasidenib, was designed as a selective inhibitor of IDH1m intended to treat patients with acute myeloid leukemia, myelodysplastic syndrome, gliomas and other solid tumors with IDH1 mutations. We will present on 2 glioma abstracts at the 2019 Society for NeuroOncology Annual Meeting this November.
We have a new website to tell our story of propelling #FORMA on a new trajectory with a patient-focused mission and a robust pipeline of novel medicines with the potential to transform lives. Check out our current job openings and our clinical development programs in #sicklecell disease, acute myeloid #leukemia, #glioma and #NASH. http://glassdoor.com/slink.htm?key=vM0T7
